Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

▤ Summary

Dyadic highlights growing interest in its C1 protein production platform as Ebola preparedness efforts raise demand for faster biologics manufacturing. The company says the platform can help accelerate vaccine antigen and monoclonal antibody development, with collaborations tied to Scripps Research, CEPI-related proposals, and European biomanufacturing initiatives. Dyadic also points to recent commercial milestones across life sciences, food, nutrition, and industrial markets, including recombinant albumin, DNase I, and bovine chymosin. The release frames C1 and Dapibus as broader commercialization platforms aimed at multiple protein-production markets, not just outbreak response.

▦ Linked Companies